Drug data last refreshed 12h ago · AI intelligence enriched 6d ago
HELIUM, USP is an inhaled gas product approved by the FDA in June 2020 as a pharmaceutical-grade therapeutic agent. The exact clinical indication is not specified in available data, but inhaled helium formulations are typically used in respiratory applications. This product represents a unique modality in the pharmaceutical space with a simple delivery mechanism.
Peak lifecycle stage suggests mature commercial operations, though limited job openings (2 linked positions) indicate a small, specialized team.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Career opportunities with HELIUM, USP are extremely limited, with only 2 linked positions, both entry-level or academic in nature. This niche product appears to operate with a small team, primarily seeking IT support rather than traditional pharma commercial or medical roles.
2 open roles linked to this drug